182 filings
6-K
IFRX
InflaRx N.V.
24 Jun 24
Current report (foreign)
4:16pm
6-K
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
6-K
IFRX
InflaRx N.V.
21 May 24
Report of Foreign Private Issuer
4:15pm
6-K
IFRX
InflaRx N.V.
8 May 24
Report of Foreign Private Issuer
8:43am
6-K
IFRX
InflaRx N.V.
25 Apr 24
Report of Foreign Private Issuer
4:15pm
6-K
42l vnwfdxh9np5
4 Apr 24
Current report (foreign)
4:01pm
6-K
6emg yktcspwr6l
21 Mar 24
Corporate Presentation March 2024
5:00pm
6-K
y3ztm059
21 Mar 24
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
7:05am
6-K
zzrtv3utbzwoyzp6
25 Jan 24
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
8:00am
6-K
3qiklhyelb4ab3zpw
4 Jan 24
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4:16pm
6-K
34n3n rdz
6 Nov 23
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
8:00am
6-K
n03 u7fenr
1 Nov 23
Current report (foreign)
8:04am
6-K
9qhm6 6gq
11 Sep 23
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
8:45am
6-K
7mgucbkuj 06bynja
30 Aug 23
Current report (foreign)
8:00am
6-K
pnsa82 m8
10 Aug 23
Report of Foreign Private Issuer
8:00am
EFFECT
58xvqa4 hh9uq
12 Jul 23
Notice of effectiveness
12:15am
424B5
tm2j74
12 Jul 23
Prospectus supplement for primary offering
12:00am
CORRESP
ftjedr
7 Jul 23
Correspondence with SEC
12:00am
UPLOAD
nkd1f06
6 Jul 23
Letter from SEC
12:00am